Serum concentrations of asprosin in new-onset type 2 diabetes

Background: Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status . Methods: This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants . Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA). Results: In patients with T2DM, the serum concentrations of asprosin were significantly higher than the healthy controls (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P< 0.001). The concentrations of asprosin were significantly correlated with body mass index (BMI) and fasting blood glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin check index (QUICKI), triacylglycerol (TAG) and total cholesterol/ high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM group. In fully adjusted model, the odds ratio (OR) of T2DM with serum concentrations of asprosin was approximately 1.547 (95% CI 1.293-1.850, P< 0.001) compared to the control group . Multiple stepwise regression analysis indicated that FBG and HOMA-IR were independently associated with asprosin in T2DM. Conclusion : Our findings indicated that serum concentrations of asprosin are increased in patients with T2DM. Also, asprosin is correlated with insulin resistance and TC/HDL-C ratio (atherosclerotic risk factor of cardiovascular diseases) in patients with T2DM.


Background
Obesity is a strong risk factor of type 2 diabetes mellitus (T2DM) (1). The global growth of obesity largely explains the reason behind the dramatic increase in the incidence and prevalence of T2DM over the past 20 years (2). However, the mechanisms that link these conditions are not fully understood (3). Improving our knowledge about underlying mechanisms can lead to the identification and development of new treatment options.
Adipokines are cytokines secreted from adipose tissue, which affect a broad spectrum of biological processes (4)(5)(6)(7). Some of these adipokines, such as resistin and leptin, antagonize insulin function in peripheral tissues, especially in the liver and skeletal muscles, that leads to insulin resistance (7)(8)(9). In contrast, adiponectin increases insulin sensitivity (10,11). The balance between adipokines is thought to play an important role in regulating insulin sensitivity (12). Asprosin, a new adipokine, was identified in 2016 by Romere .et al (13). This adipokine is produced in response to starvation in adipocytes due to the breakdown of the C-terminal domain of profibrillin (13). Asprosin rapidly releases glucose from liver cells by activating the G protein-cAMP-PKA pathway (13). The olfactory receptor (OLFR734) acts as a receptor for asprosin in hepatocytes and is involved in hepatic glucose production (14). Olfr734 knockout mice have been shown a poor response to asprosin, low cAMP and glucose production, and increased insulin sensitivity (15). Some studies have shown that serum concentration of asprosin is associated with insulin sensitivity (14,(16)(17)(18)(19). Injection of recombinant asprosin increases glucose and causes hyperinsulinemia, while injection of anti-asprosin antibodies improves glucose tolerance and insulin resistance (13). Elevated serum asprosin concentrations are pathophysiologically in patients with metabolic syndrome (13). The association between asprosin and T2DM has been investigated in some studies (18)(19)(20); however, for two major reasons, more evidence is needed to confirm the role of asprosin in the development of T2DM. Firstly, ethnic variation usually affects adipokines concentrations. The results of studies carried out in different population suggest that inconsistent results may be obtained when adipokines are examined in different populations (21)(22)(23)(24). Secondly, some of the contradictory results are observed regarding the correlation of asprosin with lipid metabolism in previous studies (14,19,20). Therefore, this observational study was designed to compare serum concentration of asprosin in new onset T2DM patients with healthy subjects.

5 Assessment of serum asprosin concentrations
Serum asprosin concentrations were determined by a commercial enzyme-linked immunosorbent (ELISA) kit according to the manufactures instructions (Cat.NO: CK-E91570; EASTBIOPHARM, China). The intra-assay coefficient of variation was < 10%, and the interassay coefficient of variation was < 12%.

6 Statistical analysis
All statistical analyses were conducted by SPSS software version 23.0 (IBM, Armonk, NY).
The distribution of the data was tested by the Shapiro-Wilk test. Mann-Whitney and t-test were used to compare the continuous difference variables between groups. A chi-squared test was applied for comparing categorical variables between groups. The participants were divided into three groups based on asprosin concentration with cutoff 3 ng/ml, and analysis of variance (ANOVA) was performed for group comparison. Correlation between different variables and asprosin concentrations was tested using Spearman correlation coefficient. Multivariate logistic regression analysis was used to analyze the association between serum concentrations of asprosin and T2DM. Moreover, linear stepwise regression model has applied to develop a model based on potential predictor variables. P values < 0.05 were regarded as statistically significant.

1 General characteristics of individuals
The clinical parameters of the 194 participants are shown in Table 1. FBG, HbA1c, TAG, LDL-C and fasting insulin concentrations, LDL-C/HDL-C and TC/HDL-C ratio and HOMA-IR were significantly higher in patients with T2DM than in the control group. However, HDL-C concentration, HOMA-, HOMA-S and QUICKI were significantly lower in patients with T2DM compared to the control group. There was no significant difference between TC in the two groups ( Table 1). The serum concentration of asprosin was significantly higher in T2DM patients compared to healthy controls ( Figure 1).

2 Asprosin concentration and clinical parameters
Spearman correlation analysis showed that in the control group, serum concentrations of asprosin were significantly correlated with BMI (r = 0.454, P< 0.001) and FBG (r = 0.720, P< 0.001) ( Table 2). In the T2DM group, asprosin was positively correlated with BMI (r =

3 Serum concentrations of asprosin and T2DM
All subjects were divided into tertiles based on serum concentrations of asprosin (T1: <3 ng/ml, T2: 3-6 ng/ml and T3:> 6 ng/ml). The clinical parameters for each category are listed in Table 4. Parameters such as BMI, FBG, HbA1c, fasting insulin, TAG, HDL-C, TAG/HDL-C, and HOMA-IR increased in correspondence to tertiles. Parameters such as HOMA-B, HOMA-S and QUICKI decreased in correspondence to tertiles. The trend Chisquare test showed that the number of T2DM patients increased with elevation of asprosin concentrations among the tertiles (Figure 3). Only patients with T2DM were placed in the third tertile.
As shown in

Discussion
To the best of our knowledge, this is the first study on the association between serum concentrations of asprosin and lipid ratio used to predict the risk of cardiovascular disease in patients with T2DM. Also, our study adds to the limited available evidence on the association of asprosin and T2DM status.
We observed serum concentrations of asprosin in patients with T2DM are significantly higher than healthy controls. There was a positive and significant correlation between asprosin and FBG, HbA1c, TAG, HOMA-IR and TC/HDL-C ratio in T2DM patients. Also, serum concentrations of asprosin in subjects with T2DM were negatively and significantly correlated with QUICKI, HOMA-B, and HOMA-S. We found that regardless the T2DM situation, subjects with higher BMI had higher concentrations of asprosin compared to individuals with lower BMI.

Interpretion of results
In the present study, serum concentrations of asprosin in patients with T2DM were significantly higher than healthy controls. Also, while subjects were divided into tertiles, There was a significant relationship between serum concentrations of asprosin and BMI in both T2DM patients and healthy controls. However, the relationship between asprosin and BMI was not clear.  reported that serum concentrations of asprosin were significantly correlated with adiposity-related parameters such as BMI, waist circumference and waist-hip ratio in T2DM, but in non-diabetic subjects, no significant relationship was found between asprosin and these parameters. However, in their study, there was a weak positive association between asprosin and BMI in the healthy group (19). Wang et al. 2018 reported that asprosin had only a significant relationship with waist-hip ratio (18). Therefore, further studies are needed to investigate the association between obesity-related parameters and serum concentrations of asprosin.
Our results showed that, asprosin was significantly correlated with serum TAG concentration and TC/HDL-C ratio in T2DM patients, but there was no significant relationship between TAG concentration and TC/HDL-C ratio in healthy subjects. The TC/HDL-C ratio is used to predict the risk of ischemic heart disease (29). According to prospective studies, increased TC/HDL-C ratio is associated with the higher risk of cardiovascular disease (30  (19), we did not observe a relationship between asprosin and HDL-C concentrations in both groups.

Biological plausibility
The association between asprosin and insulin resistance has been shown in previous studies (17,19,20,32). Lee et al. 2019 showed that asprosin impair insulin function. They treated MIN6 cells and primary human islets with recombinant asprosin and showed that asprosin in a dose-dependent manner induced inflammatory response, cellular dysfunction, and apoptosis in these cells (32). Also, changes in lipid metabolism may also be due to insulin resistance induction in the liver (33). Several studies have shown that insulin modulates the metabolism of TAG by mechanisms such as activating or inactivating metabolic pathways enzymes or altering gene expression (33).

Limitations
Finally, our study has several limitations. The sample size was relatively limited and the findings of this study required to confirm in other ethnicities. Our obervational design had limited capability to address the underlying signaling pathways. We were unable to investigate the effect of other factors that may have an impact on asprosin secretion, such as diet and physical activity. Also, we used BMI as the only adiposity index to examine the relationship between the asprosin and obesity and the correlation with other indexes were not investigated.

Conclusion
We

Acknowledgment
This study was supported by Sabzevar University of Medical Sciences. We are grateful to all the individuals who participated in this study.

Ethics approval and consent to participate
All participants of this observational study signed consent form approved by the Ethics Committee of Sabzevar University of Medical Sciences (Code of Ethics: IR.MEDSAB.REC.1398.39) before including to study.

Competing interests
There are no conflicts of interest.

Authors' contributions
All